eBioHippo

eBioHippo is a biotechnology company focused on developing innovative therapies by targeting the Hippo signaling pathway, a critical regulator of organ size, tissue regeneration, and tumor suppression. The company utilizes a proprietary drug discovery platform to identify small molecules and biologics that modulate key components of the pathway, such as YAP/TAZ and LATS1/2 kinases. Their primary therapeutic focus is on oncology, specifically targeting Hippo-mutated or YAP-dependent solid tumors like mesothelioma and liver cancer, as well as applications in regenerative medicine. By addressing the 'undruggable' challenges of the Hippo pathway, eBioHippo aims to provide first-in-class treatments for patients with high unmet medical needs.